ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO538

Cost-Effectiveness Analysis of Paricalcitol and Calcitriol in Beijing Patients With Secondary Hyperparathyroidism

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Zhou, Jiannan, Beijing Aerospace General Hospital, Beijing, China

To compare the cost efficacy analysis and the effect on calcium and phosphorus variability of paricalcitol and calcitriol in the treatment of hemodialysis CKD-MBD patients in Beijing from the payer's perspective.


Patients were divided into the paricalcitol group and the calcitriol group, and both groups could be treated with a combination of cinacalcet. The treatment duration was 6 months, and the attainment endpoint was mean iPTH ≤ 300 pg/ml in the 4th-6th month of treatment. Efficacy was the attainment rate of patients in both groups. The cost is the sum of medications and laboratory tests over a 6-month period. We evaluated incremental cost-efficacy analysis (ICER) and plotted to scatter plots of incremental cost-effects using nonparametric Bootstrap repeated sampling 1000 times. A one-way sensitivity analysis of factors affecting ICER was also performed, and probabilistic sensitivity analysis of parametric random sampling was performed using Monte Carlo simulation.


The effective rates in the two groups were 88.7% (paricalcitol group) and 56.5% (calcitriol group), respectively. The cost-effect basis analysis showed that the ICER of paricalcitol and calcitriol and was CNY 41554.702. Single-factor sensitivity analysis showed that the price of paricalcitol is the most sensitive factor,and the probabilistic sensitivity analysis showed that paricalcitol was a more economical solution when the willingness to pay(WTP) was above CNY 32500. There is no differences of the calcium and phosphorus smoothing index between tow groups.


Paricalcitol has an economic advantage when the six-month willingness to pay is CNY 32,500 or more per effective patient treated.